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Nearly 90 years ago, Drury and Szent-Györgyi revealed that adenosine produced profound
hypotension and bradycardia, and it affected kidney function in mammals [1]. Since then,
the physiological role and potential therapeutic use of adenosine have been extensively explored [2,3].
Adenosine is considered a retaliatory metabolite [4], thus increasing oxygen supply and decreasing
oxygen consumption. Consequently, this purine nucleoside can potentially regulate a large amount
of physiological processes, including respiratory regulation, hormone action, neural function,
platelet aggregation, lymphocyte differentiation, and vascular tone. In addition, adenosine exerts
a negative chronotropic and dromotropic effect on the heart, as well as it mediates the inhibition of
neurotransmitters release and lipolysis. Interestingly, while adenosine can promote coronary artery
dilatation [5], it can induce small renal blood vessels contraction, thus opposite effects (i.e., vasodilatation
vs. vasoconstriction, respectively) could be observed depending on the physiological territory
studied [6]. Overall, it has been assumed that this purine nucleoside is a mediator of metabolic
distress, thus having considerable impact on homeostatic cellular functioning.
In 1972, it was demonstrated that electrical stimulation of brain slices prompted adenosine
release [7]. Importantly, this released adenosine induced an increase in intracellular cAMP levels,
a phenomenon that was blocked by methylxanthines (i.e., caffeine and theophylline) [8,9]. Indeed,
these observations constituted the first piece of evidence pointing to the existence of specific
plasma membrane adenosine receptors (ARs). Conversely, it was also demonstrated that the
adenosine-mediated antilipolytic effect occurred with a concomitant reduction in cAMP [10].
Overall, this dual effect of adenosine on cAMP formation ended with the first subclassification of ARs
into A1 and A2 [11], which were assumed to be G protein-coupled receptors (GPCRs). Interestingly,
four subtypes of ARs have been identified so far, namely A1R, A2AR, A2BR, and A3R, showing
differential pharmacological profile, tissue distribution, and effector coupling [12].
The following special issue of Molecules is designed to summarizes the main aspects of the state of
the art of ARs, paradigm of purinergic GPCRs, providing to the reader with the recent developments
in ARs ligands and their potential therapeutic utility. Accordingly, four review articles highlight the
pharmacotherapeutic usefulness of ARs selective agonists and antagonists. Geldenhuys et al. review
the role of adenosine in cardiovascular function and discuss these ARs ligands that have been identified
so far, modulating the cardiovascular adenosinergic system [13]. Thus, the authors emphasize on how
small changes in ligand structure impact ligand potency and efficacy [13]. Therefore, considering the
importance of adenosine signaling in the cardiovascular system, ARs represent a valuable class of drug
targets with extraordinary therapeutic potential to treat people with high blood pressure and related
cardiovascular disorders. Interestingly, Sousa and Diniz further review the current development
ARs-based drugs in the therapeutic of vasculature-related diseases [14]. Thus, the authors highlight
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the renewed interest in developing ARs ligands for cardiovascular pathologies (i.e., hypertension,
heart failure and stroke), which is reflected by the increased number of recent patents and clinical trials
involving the adenosinergic system in the pharmacotherapy of cardiovascular diseases [14]. In the
Central Nervous System (CNS), adenosine has been shown to play a key regulatory role, acting as
a presynaptic, postsynaptic, and/or non-synaptic neuromodulator [15]. Extracellular adenosine in
the brain is related to the intracellular concentration of adenosine and nucleotides, such as ATP, AMP,
and cAMP [16]. Interestingly, in some brain areas like the striatum, it has been proposed that the main
source of extracellular adenosine is the intracellular cAMP [17]. Thus, striatal extracellular adenosine
would mostly reflect an increased activation of receptors positively linked to adenylyl cyclase. Stockwell
et al. discuss the role of CNS A1R and A2AR in both normal and pathological conditions, and they
outline the potential therapeutic use of these receptors in neurodegenerative diseases (i.e., Parkinson’s
disease, PD) [18]. In addition, the authors highlight the cross-talk between A1R and A2AR, supported by
the existence A1R/A2AR heteromers [19], and its role in several neurodegenerative disorders, including
ischemia, stroke, epilepsy, and PD [18]. Finally, Ciancetta and Jacobson review the structure-based
molecular modeling applied to elucidate the binding of agonists to the A3R. The authors discussed
the challenges associated with an accurate prediction of the receptor extracellular vestibule through
homology modeling from the available X-ray templates [20]. Indeed, A3R agonists have emerged as
promising antinociceptive agents, as well as for the treatment of rheumatoid arthritis, psoriasis, and
hepatocellular carcinoma [20].
Subsequently, four research articles assess new ARs functional, mechanistic, and medicinal
chemistry prospects. Thus, Arin et al. evaluate the expression of A2BR and adenosine deaminase
(ADA) in rabbit gastric mucosa enterochromaffin-like (ECL) cells [21]. The authors identify A2BR
and ADA at the cell surface of histamine-producing ECL cells originating from the body of the
rabbit stomach, which upon A2BR challenge the receptor couples to Gs protein. Collectively, these
results shed light into the role of adenosine in the physiology of histamine secretion in ECL cells [21].
Indeed, this is an important physiological discovery considering the elevated local adenosine levels
found during inflammation of the gastric mucosa, which may blow histamine production in ECL
cells and contribute to modulate acid secretion. Next, Zsuga et al. provide an in silico qualitative
method assessing receptor reserve for adenosine [22]. Adenosine is an endogenous agonist with
a short half-life because of its high exposure to enzymes and transporters, thus it is difficult to
determine a reliable value for receptor reserve. Hence, the authors describe a new method to
determine receptor reserve for adenosine, transferable to other short half-live endogenous agonists,
which may allow prediction of agonist efficacy in different tissues based on the relevant receptor
reserve values [22]. Subsequently, Deganutti and Moro use an alternative computational method,
the Supervised Molecular Dynamics (SuMD) approach, to investigate the ligand-receptor recognition
pathway on a nanoseconds time scale [23]. Thus, to verify the applicability of the methodology,
the authors select two fragment-like adenosineA2AR positive allosteric modulators (PAMs) and
explore their possible recognition pathways by performing SuMD simulations in the absence or
presence of an agonist (i.e., NECA) [23]. Interestingly, the results suggest that SuMD simulations
can allow the identification of fragment-like PAMs following their receptor recognition pathways,
characterizing the possible allosteric binding sites. Finally, Fernández-Dueñas et al. describe the
synthesis of a novel bivalent ligand consisting in the covalent linking of caffeine and docosahexaenoic
acid (DHA) [24]. Indeed, the authors assessed the pharmacological activity and possible toxicity of
caffeine-DHA in a simple cellular model [24]. Caffeine, a non-selective AR antagonist, is the most
consumed psychoactive substance worldwide. It is generally used because it enhances physical and
cognitive functions, improving alertness, physical performance, and concentration, while decreasing
fatigue [25]. In addition, it has been postulated that this natural substance may have beneficial effects
in neurodegenerative diseases such as PD [26], thus behaving as an inverse agonist [27]. DHA is the
major omega-3 fatty acid present in the mammalian brain, where it is involved in many essential
processes such as neurogenesis and neurotransmission. The rationale for attaching caffeine to DHA is
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to facilitate caffeine delivery to striatal A2ARs and to increase the rate of A2AR oligomerization with
dopamine D2 receptor in the striatum [28].
Overall, we hope that this timely focused issue summarizing our current knowledge on adenosine
receptors will be of interest to a wide range of readers of the journal interested in the purinergic
field. Finally, we wish to express our best thanks to all authors and co-authors of the issue for their
commitment and to the anonymous reviewers for their excellent contributions.
Conflicts of Interest: The authors declare no conflict of interest.
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